NASDAQ:MGNX - MacroGenics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.70
  • Forecasted Upside: 18.03 %
  • Number of Analysts: 11
  • Breakdown:
  • 2 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$26.01
▲ +1.93 (8.01%)
1 month | 3 months | 12 months
Get New MacroGenics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGNX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$30.70
▲ +18.03% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for MacroGenics in the last 3 months. The average price target is $30.70, with a high forecast of $50.00 and a low forecast of $14.00. The average price target represents a 18.03% upside from the last price of $26.01.
Buy
The current consensus among 11 investment analysts is to buy stock in MacroGenics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/13/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/12/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 2 sell ratings
3/11/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 2 sell ratings
6/9/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 2 sell ratings
9/7/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 2 sell ratings
12/6/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 2 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 2 sell ratings
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 2 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2021Morgan StanleyBoost Price TargetUnderweight$14.00 ➝ $15.00N/A
i
2/26/2021Morgan StanleyBoost Price TargetUnderweight$14.00 ➝ $15.00High
i
12/22/2020HC WainwrightReiterated RatingBuy$36.00Low
i
Rating by R. Burns at HC Wainwright
12/17/2020BarclaysBoost Price TargetUnderweight$8.00 ➝ $14.00High
i
11/13/2020Morgan StanleyBoost Price TargetUnderweight$13.00 ➝ $14.00Low
i
11/5/2020SVB LeerinkLower Price TargetOutperform$38.00 ➝ $37.00High
i
10/13/2020Morgan StanleyBoost Price TargetUnderweight$12.00 ➝ $13.00Low
i
9/21/2020SVB LeerinkBoost Price TargetOutperform$35.00 ➝ $38.00High
i
8/3/2020CitigroupDowngradeBuy ➝ Neutral$25.00 ➝ $26.00High
i
7/31/2020Morgan StanleyBoost Price TargetUnderweight$11.00 ➝ $12.00High
i
7/31/2020HC WainwrightReiterated RatingBuy$40.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
7/15/2020Morgan StanleyBoost Price TargetUnderweight$6.00 ➝ $11.00Low
i
6/2/2020CitigroupBoost Price Target$15.00 ➝ $25.00Low
i
6/1/2020GuggenheimUpgradeNeutral ➝ BuyLow
i
5/29/2020SVB LeerinkBoost Price TargetOutperform$15.00 ➝ $27.00Medium
i
5/29/2020Stifel NicolausBoost Price TargetBuy$21.00 ➝ $36.00High
i
5/28/2020BTIG ResearchBoost Price TargetBuy$23.00 ➝ $35.00High
i
5/26/2020HC WainwrightBoost Price TargetBuy$22.00 ➝ $40.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/17/2020NomuraReiterated RatingBuy$50.00Low
i
5/14/2020WedbushBoost Price TargetOutperform$16.00 ➝ $28.00Medium
i
Rating by D. Nierengarten at Wedbush
5/12/2020Credit Suisse GroupBoost Price TargetOutperform$13.00 ➝ $30.00High
i
5/6/2020WedbushReiterated RatingOutperformHigh
i
Rating by D. Nierengarten at Wedbush
5/6/2020Credit Suisse GroupLower Price TargetOutperform$17.00 ➝ $13.00High
i
5/6/2020SVB LeerinkLower Price TargetOutperform$16.00 ➝ $15.00High
i
5/6/2020HC WainwrightBoost Price TargetBuy$18.00 ➝ $22.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
3/4/2020BarclaysInitiated CoverageUnderweight$8.00Medium
i
3/2/2020Credit Suisse GroupLower Price TargetOutperform$26.00 ➝ $17.00Low
i
2/26/2020HC WainwrightReiterated RatingBuy$18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
2/26/2020Stifel NicolausLower Price TargetBuy$21.00 ➝ $20.00High
i
2/26/2020CitigroupLower Price TargetBuy$18.00 ➝ $15.00High
i
1/21/2020WedbushBoost Price TargetOutperform$14.00 ➝ $16.00High
i
12/20/2019HC WainwrightReiterated RatingBuy$18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/18/2019Cantor FitzgeraldInitiated CoverageOverweight$17.00Medium
i
Rating by V. Kumar at Cantor Fitzgerald
12/12/2019BTIG ResearchReiterated RatingBuy ➝ Positive$23.00High
i
12/12/2019Nomura SecuritiesReiterated RatingBuy$50.00High
i
12/10/2019HC WainwrightReiterated RatingBuy$18.00High
i
12/10/2019CowenReiterated RatingBuyN/A
i
11/21/2019Morgan StanleyDowngradeEqual ➝ Equal Weight$17.00 ➝ $6.00High
i
Rating by David Lebovitz at Morgan Stanley
11/20/2019GuggenheimInitiated CoverageHoldHigh
i
Rating by Etzer Darout at Guggenheim
11/7/2019CitigroupLower Price TargetBuy$39.00 ➝ $18.00Low
i
10/23/2019HC WainwrightLower Price TargetBuy$39.00 ➝ $18.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
10/23/2019SVB LeerinkLower Price TargetOutperform$26.00 ➝ $18.00High
i
10/23/2019WedbushLower Price TargetOutperform$23.00 ➝ $14.00High
i
Rating by D. Nierengarten at Wedbush
8/1/2019Stifel NicolausLower Price TargetBuy$29.00 ➝ $25.00High
i
7/18/2019WedbushReiterated RatingOutperform$27.00Low
i
Rating by D. Nierengarten at Wedbush
6/5/2019Morgan StanleySet Price TargetHold$19.00Low
i
Rating by David Lebovitz at Morgan Stanley
6/5/2019Stifel NicolausLower Price TargetBuy$36.00 ➝ $29.00Low
i
6/5/2019WedbushReiterated RatingOutperform$26.00 ➝ $27.00High
i
Rating by D. Nierengarten at Wedbush
6/5/2019CowenReiterated RatingBuyHigh
i
5/3/2019WedbushUpgradeNeutral ➝ Outperform$26.00Low
i
Rating by D. Nierengarten at Wedbush
5/2/2019HC WainwrightReiterated RatingBuy$39.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/2/2019CowenReiterated RatingBuyHigh
i
4/17/2019Credit Suisse GroupInitiated CoverageOutperform$29.00High
i
4/12/2019GuggenheimInitiated CoverageNeutralMedium
i
4/4/2019HC WainwrightReiterated RatingBuy$39.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
2/20/2019HC WainwrightSet Price TargetBuy$39.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
2/7/2019Nomura SecuritiesBoost Price TargetBuy$41.00 ➝ $50.00Medium
i
2/7/2019SunTrust BanksBoost Price TargetBuy$40.00High
i
2/7/2019WedbushDowngradeOutperform ➝ NeutralHigh
i
Rating by D. Nierengarten at Wedbush
2/7/2019CitigroupUpgradeSell ➝ Buy$10.00 ➝ $39.00High
i
2/6/2019Raymond JamesUpgradeUnderperform ➝ Market Perform$26.80High
i
Rating by Reni Benjamin at Raymond James
2/6/2019HC WainwrightReiterated RatingPositive ➝ Buy$34.00 ➝ $39.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
2/4/2019CitigroupDowngradeNeutral ➝ Sell$22.00 ➝ $10.00High
i
1/22/2019WedbushReiterated RatingOutperform ➝ Positive$44.00 ➝ $20.00High
i
Rating by D. Nierengarten at Wedbush
1/21/2019Raymond JamesReiterated RatingSellHigh
i
Rating by Reni Benjamin at Raymond James
12/10/2018Morgan StanleySet Price TargetHold$21.00High
i
Rating by David Lebovitz at Morgan Stanley
12/10/2018Raymond JamesDowngradeOutperform ➝ UnderperformHigh
i
12/5/2018HC WainwrightSet Price TargetBuy$34.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
11/29/2018HC WainwrightSet Price TargetBuy$34.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
11/8/2018HC WainwrightSet Price TargetBuy$34.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
10/30/2018HC WainwrightReiterated RatingBuy$34.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
9/10/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$30.00Low
i
8/8/2018CowenReiterated RatingBuyMedium
i
8/8/2018HC WainwrightReiterated RatingBuy$34.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/4/2018HC WainwrightSet Price TargetBuy$34.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/31/2018Evercore ISIInitiated CoverageOutperform$33.00Medium
i
5/8/2018WedbushReiterated RatingOutperform$44.00High
i
5/8/2018HC WainwrightSet Price TargetBuy$34.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
4/6/2018SVB LeerinkReiterated RatingOutperformHigh
i
Rating by J. Chang at SVB Leerink LLC
3/14/2018Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$18.00 ➝ $26.00Medium
i
3/5/2018HC WainwrightInitiated CoverageBuy ➝ Buy$38.00High
i
Rating by D. Chattopadhyay at HC Wainwright
1/24/2018CowenReiterated RatingBuyLow
i
Rating by Boris Peaker at Cowen Inc
1/23/2018SunTrust BanksReiterated RatingBuy$31.00High
i
1/23/2018BTIG ResearchReiterated RatingBuy$28.00High
i
12/11/2017Raymond JamesReiterated RatingBuyMedium
i
Rating by Reni Benjamin at Raymond James
11/10/2017CitigroupBoost Price TargetNeutral$18.00 ➝ $22.00N/A
i
10/25/2017CowenReiterated RatingBuyN/A
i
Rating by Boris Peaker at Cowen Inc
9/12/2017Stifel NicolausReiterated RatingBuy$34.00High
i
9/11/2017WedbushReiterated RatingOutperform$44.00High
i
9/1/2017SunTrust BanksReiterated RatingBuy$26.00High
i
8/7/2017Morgan StanleyLower Price TargetEqual Weight$22.00 ➝ $21.00Low
i
8/4/2017CowenReiterated RatingBuyLow
i
5/8/2017Morgan StanleyLower Price TargetEqual Weight$24.00 ➝ $22.00Low
i
3/31/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$26.00High
i
3/6/2017BTIG ResearchReiterated RatingBuy$35.00 ➝ $28.00N/A
i
3/1/2017CowenReiterated RatingBuyN/A
i
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$41.00N/A
i
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
i
3/1/2017Roth CapitalSet Price TargetBuy$40.00N/A
i
Rating by Mark Breidenbach at Roth Capital
3/1/2017Stifel NicolausReiterated RatingBuy$51.00 ➝ $42.00N/A
i
1/25/2017CitigroupLower Price TargetNeutral$32.00 ➝ $24.00N/A
i
12/19/2016SunTrust BanksInitiated CoverageBuy$30.00N/A
i
11/16/2016Roth CapitalReiterated RatingBuyN/A
i
Rating by M. Breidenbach at Roth Capital
11/7/2016BTIG ResearchReiterated RatingBuy$35.00N/A
i
11/3/2016WedbushReiterated RatingOutperform$52.00N/A
i
9/7/2016CowenInitiated CoverageOutperformN/A
i
8/4/2016CitigroupDowngradeBuy ➝ Neutral$27.00 ➝ $32.00N/A
i
6/30/2016Morgan StanleyReiterated RatingHoldN/A
i
Rating by Matthew Harrison at Morgan Stanley
6/14/2016OppenheimerReiterated RatingBuyN/A
i
5/22/2016BTIG ResearchReiterated RatingBuy$35.00N/A
i
Rating by Dane Leone at BTIG Research
5/19/2016Morgan StanleyReiterated RatingHoldN/A
i
Rating by Matthew Harrison at Morgan Stanley
5/19/2016SVB LeerinkReiterated RatingOutperform$47.00N/A
i
5/18/2016WedbushReiterated RatingOutperform$52.00N/A
i
5/4/2016WedbushReiterated RatingOutperform$52.00N/A
i
4/8/2016Morgan StanleyBoost Price Target$20.00 ➝ $21.00N/A
i
4/7/2016BTIG ResearchInitiated CoverageBuy$35.00N/A
i
(Data available from 3/6/2016 forward)
MacroGenics logo
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3 for treating acute myeloid leukemia; MGA012, an investigational monoclonal antibody targeting PD-1; MGD013, a monoclonal antibody that targets the PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing combination of MGD009 and MGA012; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD014, a DART molecule that targets envelope protein of human immunodeficiency virus infected cells and T cells. MacroGenics, Inc. has strategic collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was founded in 2000 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $26.01
$23.53
$26.16

50 Day Range

MA: $21.72
$18.99
$25.01

52 Week Range

Now: $26.01
$4.04
$32.18

Volume

1,370,261 shs

Average Volume

793,611 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.4

Frequently Asked Questions

What sell-side analysts currently cover shares of MacroGenics?

The following sell-side analysts have issued stock ratings on MacroGenics in the last twelve months: Barclays PLC, BTIG Research, Citigroup Inc., Credit Suisse Group AG, Guggenheim, HC Wainwright, Morgan Stanley, Nomura, Stifel Nicolaus, SVB Leerink LLC, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for MGNX.

What is the current price target for MacroGenics?

10 Wall Street analysts have set twelve-month price targets for MacroGenics in the last year. Their average twelve-month price target is $30.70, suggesting a possible upside of 18.0%. Nomura has the highest price target set, predicting MGNX will reach $50.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $14.00 for MacroGenics in the next year.
View the latest price targets for MGNX.

What is the current consensus analyst rating for MacroGenics?

MacroGenics currently has 2 sell ratings, 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MGNX will outperform the market and that investors should add to their positions of MacroGenics.
View the latest ratings for MGNX.

What other companies compete with MacroGenics?

How do I contact MacroGenics' investor relations team?

MacroGenics' physical mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company's listed phone number is 301-251-5172. The official website for MacroGenics is www.macrogenics.com.